Clinical Trial Update: A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update of pegylated liposomal doxorubicin with cyclophosphamide in HER2-negative stage I–II breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: TTY Biopharm | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN